DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/r5jrks\/randd_trends_park<\/a>) has announced the addition of the \"R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term\" report to their offering. <\/p>\n Review of key trends in the development of new Parkinson's disease drugs across the seven major markets. Includes detailed analyses of the composition of the pipeline, clinical trial design, target product profile, and future treatment developments. <\/p>\n Since early 2011, R&D efforts in Parkinson's disease have been met with mixed success. In Q1 2012, the US FDA re-approved UCB's Neupro (rotigotine patch), and accepted the New Drug Application filing for Impax\/GSK's IPX066 for idiopathic Parkinson's disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy. <\/p>\n Scope <\/p>\n Highlights <\/p>\n Key Topics Covered: <\/p>\n OVERVIEW <\/p>\n EXECUTIVE SUMMARY <\/p>\n CLINICAL PIPELINE OVERVIEW <\/p>\n<\/p>\n Read the original post: DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/r5jrks\/randd_trends_park<\/a>) has announced the addition of the \"R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term\" report to their offering. Review of key trends in the development of new Parkinson's disease drugs across the seven major markets. Includes detailed analyses of the composition of the pipeline, clinical trial design, target product profile, and future treatment developments Continue reading
\nResearch and Markets: R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"